このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

女性の発毛をサポートする栄養補助食品の前向き研究

2026年11月10日 更新者:Nutraceutical Wellness Inc.

薄毛を自覚している女性の発毛をサポートする栄養補助食品に関する単一施設の前向き研究

A single site open label interventional study evaluating currently marketed hair supplements targeting the underlying root causes of thinning hair.

調査の概要

詳細な説明

A single site open label interventional study evaluating currently marketed hair supplements targeting the underlying root causes of thinning hair. All treatment regimens are commercially available nutraceutical hair growth supplements. 45 subjects will be enrolled into each of the 4 supplement groups. Subjects will undergo a baseline, baseline + 48 hours, 90 day, 90 day + 48 hours, 180 day and 180 day + 48 hours visit and will have compliance phone calls at Days 45 and 135. All subject data will be compared to baseline in paired comparison for each subject using a historical control.

研究の種類

介入

入学 (実際)

181

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • California
      • Sacramento、California、アメリカ、95815
        • Integrative Skin Science and Research

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~70年 (大人、高齢者)

健康ボランティアの受け入れ

はい

受講資格のある性別

女性

説明

Inclusion Criteria:

  1. Females of all Fitzpatrick skin, and hair types between 18-70 years of age with self-perceived thinning, confirmed by a dermatologist.
  2. Willing and able to adhere to the same dietary lifestyles for the duration of the study.
  3. Able to understand and sign an informed consent agreement and photo release form approved by the Institutional Review Board
  4. General good health, as determined by the Investigator or qualified sub-investigator.
  5. Willing and able to attend all study visits and comply with the test product daily instructions.
  6. Willing to use a mild non-medicated shampoo and conditioner for the duration of the study (medicated shampoo and conditioner refer to any prescription shampoo or conditioner as well as any over-the counter medicated shampoo or conditioner, such as those for treatment of dandruff or promoting hair growth).
  7. Willing and able to cooperate with the requirements of the study.
  8. Able to complete and understand the various questionnaires.

Exclusion Criteria:

  1. Individuals who are pregnant, planning a pregnancy, nursing, or within 1-year post-partum.
  2. Individuals who have experienced serious complications due to COVID-19 previously or during the study as determined by the investigator.
  3. Clinical diagnosis of hair loss disorder such as alopecia areata, or scarring forms of alopecia.
  4. Individuals who have had a history of any acute or chronic disease that could interfere with or increase the risk on study participation.
  5. Individuals who have had a history of any acute or chronic medical or hair condition that could affect study results, such as a history of disordered eating.
  6. Scalp hair loss on the treatment area, due to disease, injury, or medical therapy.
  7. Current skin disease (e.g., psoriasis, atopic dermatitis, skin cancer, eczema, sun damage, seborrheic dermatitis), infection, cuts, and/ or abrasions on the scalp or condition (e.g., sunburn, tattoos) on the treatment area that, in the opinion of the Investigator or qualified sub-investigator, might put the subject at risk or interfere with the study conduct or evaluations.
  8. History of surgical correction of hair loss on the scalp (i.e., hair transplant).
  9. Use of any products or devices purported to promote scalp hair growth (e.g., finasteride or minoxidil) within the 6 months prior to the Baseline Visit.
  10. Females who have recently (within the last 6 months) started the use of hormones for birth control or hormone replacement therapy (HRT). Women currently using hormones for birth control or HRT must have been on a stable dose (6 months or longer) in order to be eligible for the study (the initiation of HRT or birth control should not have been associated with the initiation of hair loss/thinning).
  11. History of malignancy (except cutaneous squamous cell carcinoma and basal cell carcinoma) or currently undergoing chemotherapy or radiation treatments.
  12. A known history of autoimmune thyroid disease, any other thyroid disorder/abnormality or other autoimmune disorders that in the opinion of the Investigator or qualified sub-investigator may interfere with the study treatment.
  13. A known history of unstable or chronic depression or bipolar disease or any other condition that may impact the subject's participation in the opinion of the investigator or qualified sub-investigator.
  14. A known allergy to any of the ingredients in the investigational product.
  15. Utilization of low-level lasers for hair growth in the last three months.
  16. Any condition that the Investigator thinks may put the subject at risk or interfere with their participation in the study or study results.
  17. Known history of or current iron deficiency, bleeding disorders or platelet dysfunction syndrome as well as subjects receiving anticoagulant therapy or smokers with usage >20 cigarettes/day as reported by the subject.
  18. Use of any medications or medicated shampoos that are known to potentially cause hair loss or affect hair growth, as determined by the Investigator or qualified sub-investigator.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Nutrafol Hair Growth Supplement

4 commercially available hair growth nutraceuticals will be evaluated. Treatment groups will be assigned according to the investigator's discretion. Efficacy comparisons will not be made across treatment groups.

Hair growth supplement for women ages 18 - 44. This product will be studied in the general women population and not postpartum women.

Hair growth supplement for women ages 18 - 44

Hair growth supplement for women ages 45 - 70

Hair growth supplement for women ages 18 - 44. This treatment group may also include subjects who do not follow a plant-based diet for purposes of extending the product claims beyond the initially studied demographic of women primarily adhering to a plant-based diet

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
The percent change in hair growth rate at Day 180 relative to baseline (Day 0)
時間枠:180 days

The percent change in hair growth rate at Day 180 relative to baseline (Day 0) using Canfield HairMetrix® non-invasive device.

180 days

二次結果の測定

結果測定
メジャーの説明
時間枠
The percent change in hair growth rate at Day 90 relative to baseline (Day 0)
時間枠:90 Days

The percent change in hair growth rate at Day 90 relative to baseline (Day 0) as measured by the Canfield HairMetrix®.

90 Days
The change in total hair count, terminal hairs, vellus hairs, anagen, and telogen hairs compared to baseline at 90 days
時間枠:90 days

The change in total hair count, terminal hairs, vellus hairs, anagen, and telogen hairs compared to baseline at 90 days as measured by the Canfield HairMetrix® compared to baseline.

90 days
The change in total hair count, terminal hairs, vellus hairs, anagen, and telogen hairs compared to baseline at 180 days
時間枠:180 days

The change in total hair count, terminal hairs, vellus hairs, anagen, and telogen hairs compared to baseline at 180 days as measured by the Canfield HairMetrix® compared to baseline.

180 days
The change in terminal to vellus ratio
時間枠:90 Days

The change in terminal to vellus ratio as measured by the Canfield HairMetrix® at 90 days compared to baseline.

90 Days
The change in terminal to vellus ratio
時間枠:180 Days

The change in terminal to vellus ratio as measured by the Canfield HairMetrix® at 180 days compared to baseline.

180 Days
The change in anagen to telogen ratio
時間枠:90 Days

The change in terminal to vellus ratio per cm2 as measured by the Canfield HairMetrix® at 90 days compared to baseline.

90 Days
The change in anagen to telogen ratio
時間枠:180 Days

The change in terminal to vellus ratio per cm2 as measured by the Canfield HairMetrix® at 180 days compared to baseline.

180 Days
The change in average number of hairs per follicular unit
時間枠:90 Days

The change in average number of hairs per follicular unit as measured by the Canfield HairMetrix® at 90 days compared to baseline.

90 Days
The change in average number of hairs per follicular unit
時間枠:180 Days

The change in average number of hairs per follicular unit as measured by the Canfield HairMetrix® at 180 days compared to baseline.

180 Days
The change in total hair width per cm2
時間枠:90 Days

The change in total hair width per cm2 as measured by the Canfield HairMetrix® at 90 days compared to baseline.

90 Days
The change in total hair width per cm2
時間枠:180 Days

The change in total hair width per cm2 as measured by the Canfield HairMetrix® at 180 days compared to baseline.

180 Days
The change in mean inter-follicular distance
時間枠:90 Days

The change in mean inter-follicular distance as measured by the Canfield HairMetrix® at 90 days compared to baseline.

90 Days
The change in mean inter-follicular distance
時間枠:180 Days

The change in mean inter-follicular distance as measured by the Canfield HairMetrix® at 180 days compared to baseline.

180 Days
Subjective assessments of change measured with Consumer Perception Questionnaire at 90 days
時間枠:90 Days

Subjective assessments of change in hair growth and appearance measured with Consumer Perception Questionnaire at 90 days

90 Days
Subjective assessments of change measured with Consumer Perception Questionnaire at 180 days
時間枠:180 Days

Subjective assessments of change in hair growth and appearance measured with Consumer Perception Questionnaire at 180 days

180 Days

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

便利なリンク

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2024年5月6日

一次修了 (実際)

2025年6月18日

研究の完了 (実際)

2025年6月18日

試験登録日

最初に提出

2024年4月11日

QC基準を満たした最初の提出物

2024年4月16日

最初の投稿 (実際)

2024年4月19日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月16日

QC基準を満たした最後の更新が送信されました

2026年11月10日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する